The company has continued discussions with the FDA to advance Halo-Lido, a treatment for hemorrhoids, into the next stages of development.
Strength and Operational Preparedness
Citius strengthened its position with a $15M offering completed in April, bringing its cash and cash equivalents to $17.9M as of June 30, 2024.
These funds are projected to sustain operations through December 2024, with the company actively exploring further capital sources to extend its financial runway beyond this period.
For the quarter ended June 30, 2024, research and development expenses were $2.8M , down from $3.8M the previous year, due to reduced costs following the completion of the Mino-Lok® trial.
General and administrative expenses rose to $4.8M , reflecting increased investments in pre-launch activities for LYMPHIR.
As Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) prepares for LYMPHIR’s market entry and the continued development of Mino-Lok® and Halo-Lido, the company remains strategically focused on resource optimization and operational readiness.
With these achievements, Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is positioned for a transformative period as it advances its late-stage therapies and prepares for commercialization, making it a compelling company to monitor in the biopharma sector.
Market Growth Strategy
Citius Pharmaceuticals is targeting multi-bill-ion-dollar global markets with high unmet needs:
- CRBSI/CLABSI Market: Projected at over $1.8B globally.
- CTCL Market: Estimated at $300-$400M in the U.S., with potential for further expansion into PTCL and immuno-oncology.
- Hemorrhoidal Treatment Market: Estimated over $2B in the U.S.
The experienced management team, led by Chairman, CEO, and Co-Founder Leonard Mazur, includes notable figures in biopharma and healthcare.
The leadership team brings decades of experience and a proven track record, further supporting the company’s clinical and commercial endeavors.
With LYMPHIR™ on the brink of reshaping CTCL care and a range of critical therapies in development, Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) has the potential to gain ground in the biopharma arena.
The company’s forward-looking strategy, robust R&D pipeline, and commitment to advancing patient care uniquely position it for long-term growth in the biopharmaceutical industry.
5 reasons why Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is #1 on our watchlist today…
1. Recent Market Recognition: Last week, Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) saw an approximate 42% move over three days. This sharp increase reflects growing market interest in the company’s achievements and upcoming product launches.
2. Analyst Coverage: Analysts at EF Hutton (now D. Boral Capital) have initiated coverage on Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) with a $6.00 target, which suggests over 1,358% in potential upside.
3. FDA-Approved Cancer Therapy: Just a few months ago, Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) secured FDA approval for LYMPHIR™ as a treatment for CTCL. This achievement marks a relatively recent milestone, solidifying the company’s growing role in oncology.
4. Strategic Spin-Off: Citius successfully spun off its oncology division through a merger, creating another company of which they own 90%. This restructuring allows each division to focus on distinct paths, amplifying growth potential in both critical care and oncology.
5. Pipeline with Diverse Market Reach: Beyond LYMPHIR™, Citius’s late-stage assets like Mino-Lok® and CITI-002 (Halo-Lido) target other high-need areas, including infections and hemorrhoidal relief, tapping into markets valued at over $1.8B and $2B, respectively.
Consider adding Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) to your radar this week…
With recent market recognition driving an approximate 42% move in under three days last week, along with an analyst’s $6 target suggesting over 1,358% potential upside, Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is one little-known biotech to have on your radar.
The company’s FDA approval for LYMPHIR™ as a CTCL treatment only a few months ago underscores its commitment to oncology, while the recent spin-off amplifies its focus on high-impact treatments across both critical care and cancer.
Backed by a diverse pipeline addressing bill-ion-dollar markets, Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is making strategic moves to maximize growth in infectious disease and hemorrhoidal relief therapies, with Mino-Lok® and Halo-Lido expected to follow LYMPHIR™ in upcoming commercialization efforts.
With the anticipated Q4 launch of LYMPHIR™, Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is positioning itself for a transformative phase in the biopharma sector.
Make no mistake!
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is #1 on our watchlist today. And don’t miss the hot off the press news about how Citius Pharmaceuticals, Inc. (Nasdaq: CTXR)’s early cancer trial results show significant promise.
Keep an eye on (CTXR) - it's currently triggering 17 Bullish Signals on TradingView’s technical analysis tool.
I’ll check back in with you shortly. |
ليست هناك تعليقات:
إرسال تعليق